SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Extreme FDA Medical Device Trades: 7 Stocks Under $5
ICAD
|
|
|
+25.20%
in
145 days
<> Below are extreme trades among companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 238 entries as of 7/5/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissio...
|
iCAD, Inc. (ICAD) Offers Tremendous Value to Investors
ICAD
|
|
|
+30.95%
in
326 days
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions designed to enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. The company provides a comprehensive array of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is currently trusted by more than a thousand women’s healthcare centers worldwide. The company has been responsible for a number of mammography CAD innovations, including: <> • the first system to offer a clear film-to-< />< />< />< />< />< /><><>...
|
From the Blogosphere
Medivation (MDVN): Drug firm targets Alzheimer's
Filed under: Newsletters, Stocks to Buy For speculative investors aware of the risks associated with a development stage drug company, Karim Rahemtulla looks to Medivation (NASDAQ: MDVN), a play on development of a drug to treat Alzheimer's. In his Xcelerated Profits Report, the advisor explains, "Medivation continues to make good clinical trial progress with its Dimebon drug for Alzheimer's Disease. <>"The firm received some mainstream media attention at the recent International Conference on Alzheimer's Disease (ICAD) in Vienna. Reuters, Forbes and Bloomberg all reported that Dimebon is chang...
|
Medivation (MDVN) targets Alzheimer's
|
|
|
 Karim Rahemtulla looks to Medivation (NASDAQ: MDVN), a play on the development of a drug to treat Alzheimer's. Here's his latest in Xcelerated Profits Report.
"Medivation continues to make good clinical trial progress with its Dimebon drug for Alzheimer’s Disease. "The firm received some mainstream media attention at the recent International Conference on Alzheimer’s Disease (ICAD) in Vienna. Reuters, Forbesand Bloomberg all reported that Dimebon is changing the way scientists think about Alzheimer’s. <>"Data showed that in mice and cell cultures, Dimebon increased the presence of amyloid...
|
MFI Stock List Additions for Week Ending February 27, 2009
|
|
|
Here are the latest additions to the MFI stock universe:
- Altera Corp. (ALTR)
- Amedisys Inc. (AMED)
- icad Inc. (ICAD)
- Ituran Location and Control Ltd. (ITRN)
- Stryker Corp. (SYK)
- Varian Medical Systems Inc. (VAR)
- Waters Corp. (WAT)
- World Fuel Services Corp. (INT)
To qualify for the list, a stock must appear for the first time in the past six months in the top 100 for any of the following minimum market cap thresholds: $1MM, $5MM, $10MM, $15MM, $20MM, $25MM, $50MM, $75MM, $100MM, $150MM, $200MM, $250MM, $300MM, $350MM, $400MM, $450MM, $500MM, $600MM, $700MM, $800MM, $900MM, $1B, $1.1B, $1.2B, $1.3B, $1.4...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ICAD |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About icad inc.
- Answers.com
